What question did this study set out to answer?

The aim is to evaluate the effect of sotagliflozin on intestinal glucose absorption using a dual glucose tracer method.

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial finds sotagliflozin lowers postprandial glucose and insulin in healthy individuals, suggesting a new approach to glucose management.

The aim is to evaluate the effect of sotagliflozin on intestinal glucose absorption using a dual glucose tracer method.
Double-blind, 3-period crossover study (NCT01916863) with 24 healthy participants.
Participants received single doses of sotagliflozin, canagliflozin, or placebo after standardized meals.
Outcome measures included rate of appearance of oral glucose, postprandial glucose, and postprandial insulin concentrations.
Sotagliflozin and canagliflozin significantly decreased AUC0-1 hour and/or AUC0-2 hours for RaO, postprandial glucose, and insulin (P < .05 versus placebo).
Sotagliflozin reduced RaO AUC0-1 hour and postprandial glucose AUC0-5 hours after a 5.25-hour postdose lunch compared to both placebo and canagliflozin (P < .05).

Powell et al. (2019) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial finds sotagliflozin lowers postprandial glucose and insulin in healthy individuals, suggesting a new approach to glucose management.